SCHEMBL13861660

SCHEMBL13861660

CC(C)(C)N1CCCC(n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 20/20 0.74
▸ LCK P06239 3/20 0.74
▸ LYN P07948 3/20 0.74
▸ NUDT14 O95848 2/20 0.69
▸ NUDT5 Q9UKK9 2/20 0.69
▸ EGFR P00533 4/20 0.68
▸ ITK Q08881 3/20 0.68
▸ TEC P42680 3/20 0.67
▸ BMX P51813 3/20 0.67
▸ TXK P42681 2/20 0.67
▸ FGFR2 P21802 2/20 0.67
▸ FLT3 P36888 2/20 0.67
▸ RIPK2 O43353 1/20 0.67
▸ NR1I2 O75469 1/20 0.67
▸ SLC22A3 O75751 1/20 0.67
▸ LATS1 O95835 1/20 0.67
▸ ABL1 P00519 1/20 0.67
▸ ERBB2 P04626 1/20 0.67
▸ FYN P06241 1/20 0.67
▸ PGR P06401 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13861659 1.00 BTK (0.74) BTKLCKLYNNUDT14NUDT5
SCHEMBL25933030 0.95 BTK (0.75) BTKLCKLYNNUDT14NUDT5
SCHEMBL24827788 0.91 BTK (0.70) BTKLCKLYNNUDT14NUDT5
SCHEMBL25933017 0.91 BTK (0.73) BTKLCKLYNNUDT14NUDT5
SCHEMBL24827859 0.90 BTK (0.68) BTKLCKLYNNUDT14NUDT5
SCHEMBL24827777 0.89 BTK (0.80) BTKLCKLYNNUDT14NUDT5
SCHEMBL25068925 0.88 BTK (0.80) BTKLCKLYNNUDT14NUDT5
SCHEMBL22737178 0.88 BTK (0.80) BTKLCKLYNNUDT14NUDT5
SCHEMBL16075638 0.88 BTK (0.80) BTKLCKLYNNUDT14NUDT5
SCHEMBL19638970 0.87 BTK (0.73) BTKLCKLYNNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 — — US disclosed
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 — — US disclosed
US-11542266-B1 Substituted piperidines as BTK inhibitors HAISCO PHARMACEUTICALS PTE. LTD. (SG) 2023-01-03 — — US disclosed
WO-2012158795-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2012-11-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542266-B1 Substituted piperidines as BTK inhibitors BTK, BLK, SYK BTK 1/4885LCK 5/4885LYN 7/4885
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 BTK 1/4885LCK 6/4885LYN 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback